会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • SILICONE HYDROGELS FOR TISSUE ADHESIVES AND TISSUE DRESSING APPLICATIONS
    • 有机硅水凝胶用于组织粘合剂和组织敷料应用
    • WO2009073401A4
    • 2009-12-03
    • PCT/US2008084306
    • 2008-11-21
    • DSM IP ASSETS BVMCCREA KEITHWARD ROBERT STIAN YUAN
    • MCCREA KEITHWARD ROBERT STIAN YUAN
    • A61L26/00
    • A61L15/60A61L15/225A61L15/26A61L26/0019A61L26/0076A61L26/008C08L83/04
    • A silicone hydrogel formulation may contains random and/or block copolymers or oligomers or macromers. The silicone copolymer is copolymerized or blended with other polymers or monomers or macromers to obtain final formulation. The silicone hydrogel may contain crosslinking groups to provide a complete or partially crosslinked final structure. The silicone hydrogel formulation may be pre-formed as a film or other structure, or it may be polymerized during application as in the case of an adhesive formulation. A wound dressing comprising a silicone hydrogel formed as a film, either prior to application to a wound or in situ on a wound, which film has gas permeability, moisture permeability, and high water content, wherein said silicone hydrogel is formed from a polymerizable silicone such as a difunctional polydimethylsiloxane methacrylate and crosslinking agents such as N,N-dimethylacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), and trimethylsiloxy silane (TRIS).
    • 硅酮水凝胶制剂可含有无规和/或嵌段共聚物或低聚物或大分子单体。 硅氧烷共聚物与其他聚合物或单体或大分子单体共聚或共混以获得最终配方。 硅酮水凝胶可以含有交联基团以提供完全或部分交联的最终结构。 硅酮水凝胶制剂可以预先形成为膜或其他结构,或者可以在施用期间如在粘合剂制剂的情况下那样聚合。 1.一种创伤敷料,其包含作为膜形成的硅酮水凝胶,所述硅酮水凝胶在应用于伤口之前或原位置于伤口上,所述膜具有气体渗透性,透湿性和高含水量,其中所述硅酮水凝胶由可聚合硅酮 如双官能聚二甲基硅氧烷甲基丙烯酸酯和交联剂如N,N-二甲基丙烯酰胺(DMA),甲基丙烯酸2-羟乙酯(HEMA)和三甲基甲硅烷氧基硅烷(TRIS)。
    • 6. 发明申请
    • BIOMARKERS FOR AGGRESSIVE PROSTATE CANCER
    • 生物标志物用于肿瘤前列腺癌
    • WO2012129408A3
    • 2013-01-31
    • PCT/US2012030129
    • 2012-03-22
    • UNIV JOHNS HOPKINSZHANG HUITIAN YUANCHAN DANIEL WCHEN JING
    • ZHANG HUITIAN YUANCHAN DANIEL WCHEN JING
    • G01N33/53G01N33/574G01N33/68
    • G01N33/6893G01N33/57434
    • The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis. In a specific embodiment, the one or more biomarkers may comprise cathepsin-L (CTSL), periostin, microfibrillar-associated protein 4 (MFAP4), collagen XII, neprilysin, clusterin, neutrophil gelatinase associated lipocalin (NGAL), epithelial cell activating molecule (EpCAM), prostate specific antigen (PSA), membrane metallo-endopeptidase (MME) and asporin (ASPN).
    • 本发明涉及生物标记领域,更具体地涉及可用于诊断侵略性前列腺癌的生物标志物。 在具体实施方案中,用于诊断患者中侵袭性前列腺癌的方法包括(a)测量从患者收集的样品中的一种或多种生物标志物的水平; 和(b)将一种或多种生物标志物的水平与与具有侵袭性前列腺癌的患者相关的相同生物标志物的预定水平和与不具有侵袭性前列腺癌的患者相关的相同生物标志物的预定水平进行比较,其中相关性 到其中一个预定义的级别提供诊断。 在一个具体的实施方案中,一种或多种生物标志物可以包含组织蛋白酶-L(CTSL),骨膜素,微原纤维相关蛋白4(MFAP4),胶原XII,起泡蛋白,聚集蛋白,嗜中性粒细胞明胶酶相关脂质运载蛋白(NGAL),上皮细胞活化分子 EpCAM),前列腺特异性抗原(PSA),膜金属内肽酶(MME)和阿泊菌(ASPN)。
    • 7. 发明申请
    • SELF-ASSEMBLING MONOMERS AND OLIGOMERS AS SURFACE-MODIFYING ENDGROUPS FOR POLYMERS
    • 自组装单体和低聚物作为表面修饰聚合物的终端
    • WO2007142683A3
    • 2008-10-30
    • PCT/US2006046586
    • 2006-12-07
    • POLYMER TECHNOLOGY GROUP INCWARD ROBERT SMCCREA KEITH RTIAN YUANPARAKKA JAMES PWANG SHANGER
    • WARD ROBERT SMCCREA KEITH RTIAN YUANPARAKKA JAMES PWANG SHANGER
    • A61K47/00
    • A61K31/785C08G18/0895C08G18/2875C08G18/288C08G18/44C08G18/6266
    • Polymers having the formula R(LE) x wherein R is a polymeric core having a number average molecular weight of from 5000 to 7,000,000 daltons and having x endgroups, E is an endgroup covalently linked to polymeric core R by linkage L, L is a divalent oligomeric chain, having at least 5 identical repeat units, capable of self-assembly with L chains on adjacent molecules of the polymer, and the moieties (LE) x in the polymer may be the same as or different from one another. Design of monomers, oligomers, or other reactive structures otherwise analogous to known Self Assembled Monolayers but with at least one reactive chemical group capable of binding them to the terminus of a polymer, so that the thiol-free SAM analogue becomes the self-assembling surface modifying endgroup of that polymer. Use of the polymer to fabricate a configured article from the surface-modified polymer or a coating or topical treatment on an article made from another material.
    • 具有式R(LE)x X的聚合物其中R是数均分子量为5000-7,000,000道尔顿并具有x个端基的聚合物芯,E是通过共价键与聚合物芯R共价连接的端基 连接L,L是具有至少5个相同重复单元的二价低聚链,其能够与聚合物的相邻分子上的L链自组装,并且聚合物中的部分(LE)x < 可以彼此相同或不同。 单体,低聚物或其它类似于已知的自组装单层的单体,低聚物或其它反应性结构的设计,但具有至少一个能够将它们结合到聚合物末端的反应性化学基团,使得无硫醇的SAM类似物变成自组装表面 修饰该聚合物的端基。 使用聚合物从表面改性的聚合物制造配置的制品,或者对由另一种材料制成的制品进行包衣或局部处理。